OVID Share Price | Ovid Therapeutics, Inc. Stock Analysis & Recommendation

Q: Is Ovid Therapeutics, Inc. overvalued or undervalued?

As of 13 August 2025, the valuation grade for Ovid Therapeutics, Inc. has moved from does not qualify to risky, indicating increased concerns about the company's financial health. Based on the available metrics, Ovid appears to be overvalued given its negative performance indicators, including a price-to-book value of 0.38 and an EV to EBITDA ratio of 0.34. The company also has a return on equity (ROE) of -33.92%, which further underscores its financial struggles.When compared to peers, Ovid's valuation ratios are less favorable; for instance, KalVista Pharmaceuticals, Inc. has a more negative EV to EBITDA of -3.6594, while Fulcrum Therapeutics, Inc. does not qualify for valuation metrics. Additionally, Ovid's stock has underperformed relative to the S&P 500 over the long term, with a 5-year return of -81.76% compared to the S&P's 96.61%. This performance reinforces the notion that Ovid is currently overvalued in the market.

Q: Is Ovid Therapeutics, Inc. technically bullish or bearish?

As of 3 September 2025, the technical trend for Ovid Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by a bullish MACD on the weekly chart and a bullish daily moving average. The KST is also bullish on the weekly timeframe. However, the monthly MACD is only mildly bullish, and the Bollinger Bands indicate a bearish stance on the monthly level. The Dow Theory presents a mixed view with a mildly bearish weekly signal and a mildly bullish monthly signal.In terms of performance, Ovid Therapeutics has shown a strong 30.79% return over the past month, significantly outperforming the S&P 500, which returned 2.33% in the same period. However, over longer periods, the stock has underperformed the benchmark, particularly over 3 years and 5 years, with returns of -41.35% and -81.76%, respectively, compared to the S&P 500's gains.

Q: How big is Ovid Therapeutics, Inc.?

Market Cap: As of Jun 18, Ovid Therapeutics, Inc. has a market capitalization of 21.50 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters ending in March 2025, Ovid Therapeutics, Inc. reported net sales of 0.55 million and a net profit of -24.97 million.Balance Sheet Snapshot: As of December 2024, the company reported shareholder's funds of 68.23 million and total assets of 92.17 million.

Q: What does Ovid Therapeutics, Inc. do?

Overview:Ovid Therapeutics, Inc. is a biopharmaceutical company engaged in developing medicines for patients and families living with rare neurological disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -10 Million (Quarterly Results - Mar 2025) Market-cap: USD 21.50 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.70 Return on Equity: -33.92% Price to Book: 0.36Contact Details:Address: 1460 Broadway Ste 15044, NEW YORK NY: 10036-7329 Tel: 1 646 6617661 Fax: 1 302 6365454 Website: http://www.ovidrx.com/

Q: Who are in the management team of Ovid Therapeutics, Inc.?

As of March 2022, the management team of Ovid Therapeutics, Inc. includes Dr. Jeremy Levin, who serves as the Chairman of the Board and Chief Executive Officer. Additionally, Mr. Bart Friedman is the Lead Independent Director, while Dr. Karen Bernstein, Dr. Barbara Duncan, and Dr. Douglas Williams serve as Independent Directors.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.04 M

Shareholding (Mar 2026)

FII

10.30%

Held by 43 FIIs

DII

77.93%

Held by 22 DIIs

Promoter

11.78%

Is Ovid Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of August 13, 2025, Ovid Therapeutics, Inc. is considered risky and overvalued due to negative financial indicators, including a price-to-book value of 0.38, an EV to EBITDA ratio of 0.34, a return on equity of -33.92%, and a significant underperformance of -81.76% over five years compared to the S&P 500's 96.61% return.

View full answer

Is Ovid Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Ovid Therapeutics has shifted to a bullish trend with strong short-term performance, showing a 30.79% return over the past month, but it has underperformed the S&P 500 over the longer term with returns of -41.35% and -81.76% over 3 and 5 years, respectively.

View full answer

How big is Ovid Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Ovid Therapeutics, Inc. has a market capitalization of 21.50 million, with recent net sales of 0.55 million and a net profit of -24.97 million for the four quarters ending in March 2025. As of December 2024, the company reported shareholder's funds of 68.23 million and total assets of 92.17 million.

View full answer

What does Ovid Therapeutics, Inc. do?

22-Jun-2025

Ovid Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for rare neurological disorders. It has a market cap of $21.50 million and reported net sales of $0 million with a net loss of $10 million as of March 2025.

View full answer

Who are in the management team of Ovid Therapeutics, Inc.?

22-Jun-2025

As of March 2022, Ovid Therapeutics, Inc.'s management team includes Dr. Jeremy Levin as Chairman and CEO, Mr. Bart Friedman as Lead Independent Director, and Drs. Karen Bernstein, Barbara Duncan, and Douglas Williams as Independent Directors.

View full answer

Compare Ovid Therapeutics, Inc. with Similar Stocks

Fulcrum Therapeutics, Inc.Third Harmonic Bio, Inc.Phibro Animal Health Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor long term growth as Operating profit has grown by an annual rate 8.14% of over the last 5 years

The company has declared positive results for the last 2 consecutive quarters

Risky -

High Institutional Holdings at 77.9%

Market Beating Performance

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 303 Million (Micro Cap)

P/E

83.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.52

Return on Equity

2.79%

Price to Book

2.32

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2026)

Net Profit:

-17 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-9.02%

6 Months

28.18%

1 Year

700.0%

2 Years

197.44%

3 Years

-37.8%

4 Years

23.4%

5 Years

-45.15%

Ovid Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-10.49%

EBIT Growth (5y)

8.14%

EBIT to Interest (avg)

-27.73

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.70

Sales to Capital Employed (avg)

0.04

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

77.90%

ROCE (avg)

ROE (avg)

12.05%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.32

EV to EBIT

-5.54

EV to EBITDA

-5.58

EV to Capital Employed

3.76

EV to Sales

32.42

PEG Ratio

0.73

Dividend Yield

ROCE (Latest)

-67.95%

ROE (Latest)

2.79%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 26 Schemes (11.42%)

Foreign Institutions

Held by 43 Foreign Institutions (10.3%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -100.00% vs 600.00% in Dec 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -275.26% vs 179.51% in Dec 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.70",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-17.80",
          "val2": "-12.20",
          "chgp": "-45.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-21.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.00",
          "val2": "9.70",
          "chgp": "-275.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-17,121.20%",
          "chgp": "1,712.12%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 1,116.67% vs 50.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 34.09% vs 49.52% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.30",
          "val2": "0.60",
          "chgp": "1,116.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-42.10",
          "val2": "-61.30",
          "chgp": "31.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-21.10",
          "val2": "-1.30",
          "chgp": "-1,523.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.40",
          "val2": "-26.40",
          "chgp": "34.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5,852.00%",
          "val2": "-109,337.50%",
          "chgp": "10,348.55%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

0.00

0.70

-100.00%

Operating Profit (PBDIT) excl Other Income

-17.80

-12.20

-45.90%

Interest

0.00

Exceptional Items

0.00

-21.00

100.00%

Consolidate Net Profit

-17.00

9.70

-275.26%

Operating Profit Margin (Excl OI)

0.00%

-17,121.20%

1,712.12%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is -100.00% vs 600.00% in Dec 2025

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is -275.26% vs 179.51% in Dec 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

7.30

0.60

1,116.67%

Operating Profit (PBDIT) excl Other Income

-42.10

-61.30

31.32%

Interest

0.00

Exceptional Items

-21.10

-1.30

-1,523.08%

Consolidate Net Profit

-17.40

-26.40

34.09%

Operating Profit Margin (Excl OI)

-5,852.00%

-109,337.50%

10,348.55%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 1,116.67% vs 50.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 34.09% vs 49.52% in Dec 2024

All Annual Results

Company CV

About Ovid Therapeutics, Inc.

Ovid Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.

Company Coordinates

Company Details

1460 Broadway Ste 15044 , NEW YORK NY : 10036-7329

Tel: 1 646 6617661

http://www.ovidrx.com/

Registrar Details